167 related articles for article (PubMed ID: 36631750)
1. SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma.
Lin J; Yan J; Deng XL; Wang CS; Wang HS
BMC Gastroenterol; 2023 Jan; 23(1):8. PubMed ID: 36631750
[TBL] [Abstract][Full Text] [Related]
2. SPATS2, negatively regulated by miR-145-5p, promotes hepatocellular carcinoma progression through regulating cell cycle.
Dong G; Zhang S; Shen S; Sun L; Wang X; Wang H; Wu J; Liu T; Wang C; Wang H; Lu T; Rao B; Ren Z
Cell Death Dis; 2020 Oct; 11(10):837. PubMed ID: 33037180
[TBL] [Abstract][Full Text] [Related]
3. SPATS2 is positively activated by long noncoding RNA SNHG5 via regulating DNMT3a expression to promote hepatocellular carcinoma progression.
Yan J; Huang QY; Huang YJ; Wang CS; Liu PX
PLoS One; 2022; 17(1):e0262262. PubMed ID: 35077478
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway.
Chen L; Yi C; Li W; Tseng Y; Zhang J; Liu J
J Cancer; 2021; 12(1):89-98. PubMed ID: 33391405
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer.
Xing J; Tian Y; Ji W; Wang X
Medicine (Baltimore); 2020 Feb; 99(9):e19230. PubMed ID: 32118724
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.
Jiayu F; Jiang Y; Zhou X; Zhou M; Pan J; Ke Y; Zhen J; Huang D; Jiang W
Aging (Albany NY); 2022 Dec; 14(23):9550-9578. PubMed ID: 36462500
[TBL] [Abstract][Full Text] [Related]
7. Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response.
Yan J; Deng XL; Ma SQ; Hui Li Y; Gao YM; Shi GT; Wang HS
BMC Complement Med Ther; 2023 May; 23(1):160. PubMed ID: 37202806
[TBL] [Abstract][Full Text] [Related]
8. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
9. Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma.
Wu H; Liu S; Wu D; Zhou H; Sui G; Wu G
Cancer Med; 2023 Apr; 12(8):10138-10155. PubMed ID: 36855818
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation-mediated epigenetic regulation of oncogenic RPS2 as a novel therapeutic target and biomarker in hepatocellular carcinoma.
Abi Zamer B; Rah B; Jayakumar MN; Abumustafa W; Hamad M; Muhammad JS
Biochem Biophys Res Commun; 2024 Feb; 696():149453. PubMed ID: 38181486
[TBL] [Abstract][Full Text] [Related]
11. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.
Wang X; Yang J; Luo L; Li X; Zhang Y
Aging (Albany NY); 2023 May; 15(10):4122-4143. PubMed ID: 37211383
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of m6A regulators associated with immune infiltration in Hepatitis B virus-related hepatocellular carcinoma.
Zhang Z; Gao W; Liu Z; Yu S; Jian H; Hou Z; Zeng P
BMC Gastroenterol; 2023 Jul; 23(1):259. PubMed ID: 37507670
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.
Lin B; Zhou X; Lin S; Wang X; Zhang M; Cao B; Dong Y; Yang S; Wang JM; Guo M; Huang J
J Mol Med (Berl); 2017 Nov; 95(11):1237-1249. PubMed ID: 28844099
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
15. ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m
Ding Y; Gong Y; Zeng H; Song G; Yu Z; Fu B; Liu Y; Huang D; Zhong Y
Aging (Albany NY); 2023 Jul; 15(13):6179-6211. PubMed ID: 37400985
[TBL] [Abstract][Full Text] [Related]
16. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.
Xiong C; Wang Z; Wang G; Zhang C; Jin S; Jiang G; Bai D
Invest New Drugs; 2021 Oct; 39(5):1439-1453. PubMed ID: 33942202
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of TMEM79 combined with SMG5 is related to prognosis, tumor immune infiltration and drug sensitivity in hepatocellular carcinoma.
Wang Y; Jin Q; Zhang S; Wang Y
Eur J Med Res; 2023 Nov; 28(1):490. PubMed ID: 37936239
[TBL] [Abstract][Full Text] [Related]
18. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
19. Matrin-3 acts as a potential biomarker and promotes hepatocellular carcinoma progression by interacting with cell cycle-regulating genes.
He H; Jamal M; Zeng X; Lei Y; Xiao D; Wei Z; Zhang C; Zhang X; Pan S; Ding Q; Tan H; Xie S; Zhang Q
Cell Cycle; 2024 Jan; 23(1):15-35. PubMed ID: 38252499
[TBL] [Abstract][Full Text] [Related]
20. ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.
Wang X; Peng H; Zhang G; Li Z; Du Z; Peng B; Cao P
BMC Med Genomics; 2023 Jul; 16(1):178. PubMed ID: 37525242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
